Multiple myeloma with malignant epidural spinal cord compression: new motor deficit, sens...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-MM-CORD-COMPRESSION |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-EHA-EMN-MM-2025 SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Red Flag Origin
| Definition | Multiple myeloma with malignant epidural spinal cord compression: new motor deficit, sensory level, severe back pain with vertebral plasmacytoma / lytic lesion + canal invasion — MM is a leading hematologic cause of MESCC |
|---|---|
| Clinical direction | hold |
| Category | organ-dysfunction |
| Shifts algorithm | ALGO-MM-1L |
Trigger Logic
{
"any_of": [
{
"finding": "spinal_cord_compression",
"value": true
},
{
"finding": "new_motor_deficit_with_back_pain",
"value": true
},
{
"finding": "vertebral_plasmacytoma_with_canal_invasion",
"value": true
},
{
"finding": "cauda_equina_syndrome",
"value": true
}
],
"type": "composite"
}
Notes
Per NCCN-MM + ESMO-MM 2023 + EHA-EMN-MM 2025: dexamethasone 40 mg PO/IV bolus, MRI whole spine, urgent RT (8 Gy ×1 or 20-30 Gy fractionated) ± neurosurgical decompression for instability/large mass; bortezomib- based induction begun in parallel (rapid cytoreduction). Direction HOLD on routine induction start until decompression initiated; priority 8. STUB — requires clinical co-lead signoff.
Used By
Indications
IND-MM-1L-DARA-RD- IND-MM-1L-DARA-RDIND-MM-1L-DVRD- IND-MM-1L-DVRDIND-MM-1L-RD- IND-MM-1L-RDIND-MM-1L-VRD- IND-MM-1L-VRDIND-MM-2L-DKD- IND-MM-2L-DKDIND-MM-4L-CILTACEL-CART- IND-MM-4L-CILTACEL-CARTIND-MM-4L-TECLISTAMAB- IND-MM-4L-TECLISTAMABIND-MM-ELDERLY-FRAIL-VRD-LIGHT- IND-MM-ELDERLY-FRAIL-VRD-LIGHTIND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCE- IND-MM-POST-ASCT-LENALIDOMIDE-MAINTENANCEIND-MM-RR-2L-CILTACEL- IND-MM-RR-2L-CILTACELIND-MM-RR-3L-CILTACEL- IND-MM-RR-3L-CILTACELIND-MM-RR-3L-ELRANATAMAB- IND-MM-RR-3L-ELRANATAMABIND-MM-RR-3L-IDECEL- IND-MM-RR-3L-IDECELIND-MM-RR-3L-TALQUETAMAB- IND-MM-RR-3L-TALQUETAMABIND-MM-RR-3L-TECLISTAMAB- IND-MM-RR-3L-TECLISTAMAB